Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IL23R | Q5VWK5 | 13/20 | 0.64 |
| ▸ | KISS1R | Q969F8 | 4/20 | 0.59 |
| ▸ | GHSR | Q92847 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30380456 | 1.00 | IL23R (0.64) | IL23RKISS1RGHSR | |
| SCHEMBL29872066 | 1.00 | IL23R (0.64) | IL23RKISS1RGHSR | |
| SCHEMBL30513340 | 1.00 | IL23R (0.64) | IL23RKISS1RGHSR | |
| SCHEMBL31619566 | 0.97 | IL23R (0.61) | IL23R | |
| SCHEMBL30276251 | 0.97 | IL23R (0.64) | IL23RKISS1RGHSR | |
| SCHEMBL30379397 | 0.97 | IL23R (0.64) | IL23RKISS1RGHSR | |
| SCHEMBL38662290 | 0.97 | IL23R (0.64) | IL23RKISS1RGHSR | |
| SCHEMBL31619557 | 0.97 | IL23R (0.64) | IL23RKISS1RGHSR | |
| SCHEMBL31091578 | 0.97 | IL23R (0.66) | IL23RGHSR | |
| SCHEMBL29507073 | 0.97 | GHSR (0.60) | IL23RKISS1RGHSR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250057998-A1 | Radiopharmaceutical and Methods | Point Biopharma, Inc. | 2025-02-20 | — | — | US | disclosed |
| EP-4486397-A1 | RADIOPHARMACEUTICAL AND METHODS | Point Biopharma, Inc. (US) | 2025-01-08 | — | — | EP | disclosed |
| WO-2023164769-A9 | RADIOPHARMACEUTICAL AND METHODS | Point Biopharma, Inc. (US) | 2024-11-07 | — | — | WO | disclosed |
| CN-118742332-A | Radiopharmaceuticals and methods | 普安生物制药有限公司 | 2024-10-01 | — | — | CN | disclosed |
| WO-2023164769-A1 | RADIOPHARMACEUTICAL AND METHODS | Point Biopharma, Inc. (CA) | 2023-09-07 | — | — | WO | disclosed |
| CN-116528904-A | Radiopharmaceuticals and methods | 普罗博开发商业中心 | 2023-08-01 | — | — | CN | disclosed |
| EP-4208468-A1 | RADIOLABELING AND FORMULATION FOR SCALE UP OF 64CU-DOTATATE | Curium US LLC (US) | 2023-07-12 | — | — | EP | disclosed |
| EP-4204011-A2 | RADIOPHARMACEUTICAL AND METHODS | Centre for Probe Development Andcommercialization (CPDC) (CA) | 2023-07-05 | — | — | EP | disclosed |
| US-20220387637-A1 | RADIOPHARMACEUTICAL AND METHODS | CENTRE FOR PROBE DEV AND COMMERCIALIZATION CPDC (CA) | 2022-12-08 | — | — | US | disclosed |
| US-11439714-B2 | Radiopharmaceutical and methods | CENTRE FOR PROBE DEVELOPMENT AND COMMERCIALIZATION (CA) | 2022-09-13 | — | — | US | disclosed |
| WO-2022051684-A1 | RADIOLABELING AND FORMULATION FOR SCALE UP OF 64CU-DOTATATE | CURIUM US LLC (US) | 2022-03-10 | — | — | WO | disclosed |
| US-20220062447-A1 | RADIOPHARMACEUTICAL AND METHODS | CENTRE FOR PROBE DEVELOPMENT AND COMMERCIALIZATION (CA) | 2022-03-03 | — | — | US | disclosed |
| WO-2022043754-A2 | RADIOPHARMACEUTICAL AND METHODS | CENTRE FOR PROBE DEVELOPMENT ANDCOMMERCIALIZATION (CPDC) (CA) | 2022-03-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220387637-A1 | RADIOPHARMACEUTICAL AND METHODS | KIT, PROKR1, LPXN | IL23R 1214/4885KISS1R 24/4885GHSR 327/4885 |
| US-11439714-B2 | Radiopharmaceutical and methods | KIT, PROKR1, LPXN | IL23R 1214/4885KISS1R 24/4885GHSR 327/4885 |
| US-20250057998-A1 | Radiopharmaceutical and Methods | KIT, PROKR1, LPXN | IL23R 1214/4885KISS1R 24/4885GHSR 327/4885 |
| US-20220062447-A1 | RADIOPHARMACEUTICAL AND METHODS | KIT, PROKR1, LPXN | IL23R 1214/4885KISS1R 24/4885GHSR 327/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.